Emergent says Ebola vaccine will take time

Emergent BioSolutions, Inc., a global specialty pharmaceutical company, recently said that the development of an Ebola vaccine will take time.

Emergent is the only company that produces a licensed anthrax vaccine, and while the company is not involved in making the Ebola vaccine, it said the process will take years to provide defense against the deadly disease, Wlix.com reports.

"Phase one is safety, phase two is selection and dose ranging, phase three we try to evaluate does it really work do we get the immune response we want," Adam Havey, the president of Emergent's biodefense division, said, according to Wlix.com. "It's not something that you can ramp up in weeks or months, you're really talking years to get something even into people."

Havey said the process of creating a vaccine and getting approval from the U.S. Food and Drug Administration can take as long as 15 years.

"(It would) probably cost organizations somewhere between $500 million to $1 billion, so it's a long expensive endeavor," Havey said, according to Wlix.com. "Things can go faster and there (are) ways to accelerate that but it's a long and expensive process to get to the finish line."

The National Institutes of Health has started working on an Ebola virus, but it has not commenced human testing. Ebola kills 60 to 90 percent of its victims, Wlix.com reports.

Organizations in this Story

National Institutes of Health

Want to get notified whenever we write about National Institutes of Health ?
Next time we write about National Institutes of Health, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.